Multiple Myeloma
Conditions
Interventions
Administration of autologeous dendritic cells combined with donor T-cells.
Sponsors
UMC Utrecht
Eligibility
Inclusion criteria
Inclusion criteria: 1. Multiple myeloma patients with relapsed disease after a non- myeloablative allo-SCT, who have not responded 3 months after a first course of DLI with 1 x 107 T cells/kg body weight; OR 2. Multiple patients who have received a non myeloablative Allo-SCT from a sibling or MUD donor for relapsed disease after a previous autologous SCT and who have not responded 3 months after a first course of pre-emptive DLI with 1 x 107 T cells/kg (1 x 106 T cells/kg, in case of MUD) cells/kg body weight; AND 3. Age 18-70 years; 4. Absence of acute GvHD > grade A; 5. Absence of extensive chronic GvHD; 6. WHO performance 0-2; 7. Absence of severe cardiac hepatic, renal, metabolic disease; 8. Written informed consent.
Exclusion criteria
Exclusion criteria: Not further specified.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Toxicity. | — |
Secondary
| Measure | Time frame |
|---|---|
| Efficacy. | — |
Contacts
Public ContactH.M. Lokhorst
University Medical Center Utrecht (UMCU), Department of Hematology (B02.226), P.O. Box 85500
Outcome results
None listed